[1] |
Hayakawa K, Matsumoto S, Ae K, et al. Risk factors for distant metastasis of dermatofibrosarcoma protuberans[J]. J Orthop Traumatol, 2016,17(3):261⁃266. doi: 10.1007/s10195⁃016⁃0415⁃x.
|
[2] |
Maghfour J, Genelin X, Olson J, et al. The epidemiology of dermatofibrosarcoma protuberans incidence, metastasis, and death among various population groups: a surveillance, epidemiology, and end results database analysis[J]. J Am Acad Dermatol, 2024,91(5):826⁃833. doi: 10.1016/j.jaad.2024.05.088.
|
[3] |
Zhang Z, Lu Y, Shi C, et al. Pediatric dermatofibrosarcoma protuberans: a clinicopathologic and genetic analysis of 66 cases in the largest institution in Southwest China[J]. Front Oncol, 2023,13:1017154. doi: 10.3389/fonc.2023.1017154.
|
[4] |
Sleiwah A, Wright TC, Chapman T, et al. Dermatofibrosarcoma protuberans in children[J]. Curr Treat Options Oncol, 2022,23(6):843⁃854. doi: 10.1007/s11864⁃022⁃00979⁃9.
|
[5] |
Wang L, Xiang YN, Zhang YH, et al. Collagen triple helix repeat containing⁃1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma[J]. Br J Dermatol, 2011,164(1):135⁃140. doi: 10.1111/j.1365⁃2133.2010.10050.x.
|
[6] |
Bagabir RA, Syed F, Shenjere P, et al. Identification of a potential molecular diagnostic biomarker in keloid disease: syndecan⁃1 (CD138) is overexpressed in keloid scar tissue[J]. J Invest Dermatol, 2016,136(11):2319⁃2323. doi: 10.1016/j.jid.2016.06.623.
|
[7] |
Qiu Y, Hu X, He X, et al. Clinicopathological and genetic findings of infantile nodular fasciitis[J]. Chin Med J (Engl), 2021,134(22):2768⁃2770. doi: 10.1097/CM9.000000000000 1727.
|
[8] |
Zulian F. Scleroderma in children[J]. Best Pract Res Clin Rheumatol, 2017,31(4):576⁃595. doi: 10.1016/j.berh.2018. 02.004.
|
[9] |
Lis⁃Święty A, Skrzypek⁃Salamon A, Ranosz⁃Janicka I, et al. Localized scleroderma: clinical and epidemiological features with emphasis on adulthood⁃ versus childhood⁃onset disease differences[J]. J Eur Acad Dermatol Venereol, 2017,31(10):1595⁃1603. doi: 10.1111/jdv.14197.
|
[10] |
温斯健, 胡彬, 杨励, 等. 隆突性皮肤纤维肉瘤50例临床病理分析[J]. 中华皮肤科杂志, 2015,48(12):840⁃843. doi: 10. 3760/cma.j.issn.0412⁃4030.2015.12.003.
|
[11] |
Eminger LA, Shinohara MM, Elenitsas R, et al. Giant cell fibroblastoma mimicking a soft fibroma arising within a dermatofibrosarcoma protuberans[J]. J Am Acad Dermatol, 2012,67(4):e137⁃e139. doi: 10.1016/j.jaad.2011.11.924.
|
[12] |
Yin L, Shi C, He X, et al. NTRK⁃rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China[J]. Pathology, 2023,55(3):362⁃374. doi: 10.1016/j.pathol. 2022.10.003.
|
[13] |
de Feraudy S, Fletcher CD. Fibroblastic connective tissue nevus: a rare cutaneous lesion analyzed in a series of 25 cases[J]. Am J Surg Pathol, 2012,36(10):1509⁃1515. doi: 10.1097/PAS.0b013e31825e63bf.
|
[14] |
Saab ST, McClain CM, Coffin CM. Fibrous hamartoma of infancy: a clinicopathologic analysis of 60 cases[J]. Am J Surg Pathol, 2014,38(3):394⁃401. doi: 10.1097/PAS.0000000000000104.
|
[15] |
Peng B, Nan X, Geng S. An isolated red plaque on the anterior chest[J]. JAMA Dermatol, 2025,161(6):652⁃653. doi: 10.1001/jamadermatol.2025.0745.
|
[16] |
Italiano A, Di Mauro I, Rapp J, et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study[J]. Lancet Oncol, 2016,17(4):532⁃538. doi: 10.1016/S1470⁃2045(15)00583⁃5.
|
[17] |
Navarrete⁃Dechent C, Mori S, Barker CA, et al. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review[J]. JAMA Dermatol, 2019,155(3):361⁃369. doi: 10.1001/jamadermatol.2018.4940.
|
[18] |
McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225[J]. J Clin Oncol, 2005,23(4):866⁃873. doi: 10.1200/JCO.2005.07.088.
|
[19] |
Rust DJ, Kwinta BD, Geskin LJ, et al. Surgical management of dermatofibrosarcoma protuberans[J]. J Surg Oncol, 2023,128(1):87⁃96. doi: 10.1002/jso.27258.
|
[20] |
Bordeaux J, Blitzblau R, Aasi SZ, et al. Dermatofibrosarcoma protuberans, version 1.2025, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2025,23(1):e250001. doi: 10.6004/jnccn.2025.0001.
|